Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome
Status:
Completed
Trial end date:
2019-12-27
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of two strengths of
Lacripep™ ophthalmic solution versus placebo administered three times daily for four weeks in
subjects with a diagnosis of Dry Eye associated with documented Primary Sjögren's Syndrome